References
- Wolfe F, Ross K, Anderson J, et al. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995;38:19-28
- Mease PJ, Clauw DJ, Gendreau RM, et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial. J Rheumatol 2009;36:398-409 [published correction appears in J Rheumatol 2009;36:661]
- Clauw DJ, Mease P, Palmer RH, et al. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther 2008;30:1988-2004 [published correction appears in Clin Ther 2009;31:446]
- Arnold LM, Gendreau RM, Palmer RH, et al. Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62:2745-56
- Branco JC, Zachrisson O, Perrot S, et al. A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia. J Rheumatol 2010;37:851-9
- Ferrera R, Palmer R, Chen W, et al. Improvements in fibromyalgia symptoms are sustained for 1 year with milnacipran treatment: results from 2 double-blind, dose-controlled extension studies [abstract]. J Pain 2009;10:S60
- Goldenberg DL, Clauw DJ, Palmer RH, et al. Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension study. Pain Med 2010;11:180-94
- Branco JC, Cherin P, Montagne A, et al. Longterm therapeutic response to milnacipran treatment for fibromyalgia. A European 1-year extension study following a 3-month study. J Rheumatol 2011;38:1403-12
- Arnold LM, Palmer RH, Ma Y. A 3-year, open-label, flexible-dosing study of milnacipran for the treatment of fibromyalgia. Clin J Pain 2013;29:1021-8
- Rudolph RL, Derivan AT. The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database. J Clin Psychopharmacol 1996;16:54-9S; discussion 9-61S
- Wernicke JF, Prakash A, Kajdasz DK, et al. Safety and tolerability of duloxetine treatment of diabetic peripheral neuropathic pain between patients with and without cardiovascular conditions. J Diabetes Complications 2009;23:349-59
- Lieberman DZ, Massey SH. Desvenlafaxine in major depressive disorder: an evidence-based review of its place in therapy. Core Evid 2009;4:67-82
- Pristiq (desvenlafaxine). New York, NY: Pfizer Inc, February 2013. Available at www.pristiq.com [Last accessed 12 November 2013]
- Cymbalta (duloxetine hydrochloride). Indianapolis, IN: Eli Lilly and Company, November 2012. Available at www.cymbalta.com [Last accessed 12 November 2013]
- Savella (milnacipran hydrochloride). New York, NY: Forest Laboratories, Inc., October 2013. Available at www.savella.com [Last accessed 12 November 2013]
- Wernicke J, Lledo A, Raskin J, et al. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies. Drug Saf 2007;30:437-55
- Pickering TG, Shimbo D, Haas D. Ambulatory blood-pressure monitoring. N Engl J Med 2006;354:2368-74
- Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-72
- Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-71
- Ghahramani P, Khariton T, Periclou A. Population PK-PD modeling of milnacipran effect on blood pressure and heart rate over 24-hour period using ambulatory blood pressure monitoring in normotensive and hypertensive patients with fibromyalgia [poster]. Presented at: The 22nd Annual Meeting of the Population Approach Group in Europe (PAGE). Glasgow, Scotland, 11–14 June 2013
- Saxe PA, Arnold LM, Palmer RH, et al. Short-term (2-week) effects of discontinuing milnacipran in patients with fibromyalgia. Curr Med Res Opin 2012;28:815-21